Current stage of interleukin 2 receptor targeted therapy.
The overview summarizes a new and selective form of immunosuppressive therapy by using anti-Interleukin-2 receptor monoclonal antibodies, which may soon become an important form of recipient treatment in organ/tissue transplantation or/and of patient treatment with auto-immune diseases.
Diamantstein
T
T
Institute of Immunology, Klinikum Steglitz, Free University Berlin West.
Kupiec-Weglinski
J W
JW
Strom
T B
TB
Tilney
N L
NL
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D051381:Rats; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014181:Transplantation Immunology / Q000187:drug effects
D000906:Antibodies; D015375:Receptors, Interleukin-2